JP2013522354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522354A5 JP2013522354A5 JP2013500620A JP2013500620A JP2013522354A5 JP 2013522354 A5 JP2013522354 A5 JP 2013522354A5 JP 2013500620 A JP2013500620 A JP 2013500620A JP 2013500620 A JP2013500620 A JP 2013500620A JP 2013522354 A5 JP2013522354 A5 JP 2013522354A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- diazaspiro
- inden
- nonane
- acetyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 methoxy, cyano, cyclopropyl Chemical group 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- ZIUDADZJCKGWKR-AREMUKBSSA-N 2-(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)-1-[2-[(1r)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1h-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]ethanone Chemical compound C([C@H](C1=CC=2)N3CC4(CCN(CC4)C(=O)CC4=CN5C=C(SC5=N4)C)C3)CC1=CC=2C1=CC(C)=NC=N1 ZIUDADZJCKGWKR-AREMUKBSSA-N 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 3
- 125000002971 oxazolyl group Chemical group 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- RIMZMWDWQJSJAV-RUZDIDTESA-N 2-(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-[2-[(1r)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1h-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]ethanone Chemical compound C([C@H](C1=CC=2)N3CC4(CCN(CC4)C(=O)CC4=CN5N=C(SC5=N4)C)C3)CC1=CC=2C1=CC(C)=NC=N1 RIMZMWDWQJSJAV-RUZDIDTESA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- CWWWNUAQMXMSGC-MUUNZHRXSA-N 1-[2-[(1r)-5-(2,6-dimethylpyrimidin-4-yl)-2,3-dihydro-1h-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]-2-(5-methoxypyridin-2-yl)ethanone Chemical compound N1=CC(OC)=CC=C1CC(=O)N1CCC2(CN(C2)[C@H]2C3=CC=C(C=C3CC2)C=2N=C(C)N=C(C)C=2)CC1 CWWWNUAQMXMSGC-MUUNZHRXSA-N 0.000 claims 1
- JYDQZHGILUYIQT-HHHXNRCGSA-N 1-[2-[(1r)-5-(5-ethylpyrimidin-2-yl)-2,3-dihydro-1h-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]-2-(5-methoxypyridin-2-yl)ethanone Chemical compound N1=CC(CC)=CN=C1C1=CC=C([C@@H](CC2)N3CC4(C3)CCN(CC4)C(=O)CC=3N=CC(OC)=CC=3)C2=C1 JYDQZHGILUYIQT-HHHXNRCGSA-N 0.000 claims 1
- 125000005955 1H-indazolyl group Chemical group 0.000 claims 1
- KMTPPHHBYJEXPO-XMMPIXPASA-N 2-(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)-1-[2-[(1r)-5-pyrimidin-2-yl-2,3-dihydro-1h-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]ethanone Chemical compound C([C@H](C1=CC=2)N3CC4(CCN(CC4)C(=O)CC4=CN5C=C(SC5=N4)C)C3)CC1=CC=2C1=NC=CC=N1 KMTPPHHBYJEXPO-XMMPIXPASA-N 0.000 claims 1
- TYYSKYJWHWZGJF-RUZDIDTESA-N 2-(4-methoxyphenyl)-1-[2-[(1r)-5-(triazol-2-yl)-2,3-dihydro-1h-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]ethanone Chemical compound C1=CC(OC)=CC=C1CC(=O)N1CCC2(CN(C2)[C@H]2C3=CC=C(C=C3CC2)N2N=CC=N2)CC1 TYYSKYJWHWZGJF-RUZDIDTESA-N 0.000 claims 1
- WUKHDLMVEFYYHY-AREMUKBSSA-N 2-(5-ethylpyridin-2-yl)-1-[2-[(1r)-5-pyrimidin-2-yl-2,3-dihydro-1h-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]ethanone Chemical compound N1=CC(CC)=CC=C1CC(=O)N1CCC2(CN(C2)[C@H]2C3=CC=C(C=C3CC2)C=2N=CC=CN=2)CC1 WUKHDLMVEFYYHY-AREMUKBSSA-N 0.000 claims 1
- JSJHUXMAZWAWGK-XMMPIXPASA-N 2-(5-methoxypyridin-2-yl)-1-[2-[(1r)-5-(1,3-thiazol-2-yl)-2,3-dihydro-1h-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]ethanone Chemical compound N1=CC(OC)=CC=C1CC(=O)N1CCC2(CN(C2)[C@H]2C3=CC=C(C=C3CC2)C=2SC=CN=2)CC1 JSJHUXMAZWAWGK-XMMPIXPASA-N 0.000 claims 1
- KEHVZGBXBDJDMH-AREMUKBSSA-N 2-(5-methoxypyridin-2-yl)-1-[2-[(1r)-5-(4-methylpyrimidin-2-yl)-2,3-dihydro-1h-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]ethanone Chemical compound N1=CC(OC)=CC=C1CC(=O)N1CCC2(CN(C2)[C@H]2C3=CC=C(C=C3CC2)C=2N=C(C)C=CN=2)CC1 KEHVZGBXBDJDMH-AREMUKBSSA-N 0.000 claims 1
- SEGKTHKDKIHNOM-AREMUKBSSA-N 2-(5-methoxypyridin-2-yl)-1-[2-[(1r)-5-(5-methylpyrimidin-2-yl)-2,3-dihydro-1h-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]ethanone Chemical compound N1=CC(OC)=CC=C1CC(=O)N1CCC2(CN(C2)[C@H]2C3=CC=C(C=C3CC2)C=2N=CC(C)=CN=2)CC1 SEGKTHKDKIHNOM-AREMUKBSSA-N 0.000 claims 1
- NATXGJPPVHDYCP-HHHXNRCGSA-N 2-(5-methoxypyridin-2-yl)-1-[2-[(1r)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1h-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]ethanone Chemical compound N1=CC(OC)=CC=C1CC(=O)N1CCC2(CN(C2)[C@H]2C3=CC=C(C=C3CC2)C=2N=CN=C(C)C=2)CC1 NATXGJPPVHDYCP-HHHXNRCGSA-N 0.000 claims 1
- NOLZCWDIRAGCGH-XMMPIXPASA-N 2-(5-methoxypyridin-2-yl)-1-[2-[(1r)-5-(triazol-2-yl)-2,3-dihydro-1h-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]ethanone Chemical compound N1=CC(OC)=CC=C1CC(=O)N1CCC2(CN(C2)[C@H]2C3=CC=C(C=C3CC2)N2N=CC=N2)CC1 NOLZCWDIRAGCGH-XMMPIXPASA-N 0.000 claims 1
- ZWFXCKJHCJRMDP-XMMPIXPASA-N 2-(5-methylpyridin-2-yl)-1-[2-[(1r)-5-(triazol-2-yl)-2,3-dihydro-1h-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]ethanone Chemical compound N1=CC(C)=CC=C1CC(=O)N1CCC2(CN(C2)[C@H]2C3=CC=C(C=C3CC2)N2N=CC=N2)CC1 ZWFXCKJHCJRMDP-XMMPIXPASA-N 0.000 claims 1
- LVILGAOSPDLNRM-UHFFFAOYSA-N 4-methylpyrimidine Chemical compound CC1=CC=NC=N1 LVILGAOSPDLNRM-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- RUAREKRRCYCLJA-MUUNZHRXSA-N n-[5-methoxy-2-[2-oxo-2-[2-[(1r)-5-pyrimidin-2-yl-2,3-dihydro-1h-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]ethyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC(OC)=CC=C1CC(=O)N1CCC2(CN(C2)[C@H]2C3=CC=C(C=C3CC2)C=2N=CC=CN=2)CC1 RUAREKRRCYCLJA-MUUNZHRXSA-N 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31552210P | 2010-03-19 | 2010-03-19 | |
| US61/315,522 | 2010-03-19 | ||
| US201161444401P | 2011-02-18 | 2011-02-18 | |
| US61/444,401 | 2011-02-18 | ||
| PCT/IB2011/051035 WO2011114271A1 (en) | 2010-03-19 | 2011-03-11 | 2,3 dihydro-1h-inden-1-yl- 2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013522354A JP2013522354A (ja) | 2013-06-13 |
| JP2013522354A5 true JP2013522354A5 (enExample) | 2014-02-06 |
| JP5496409B2 JP5496409B2 (ja) | 2014-05-21 |
Family
ID=44647714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013500620A Expired - Fee Related JP5496409B2 (ja) | 2010-03-19 | 2011-03-11 | ２，３ジヒドロ−１ｈ−インデン−１−イル−２，７−ジアザスピロ［３．５］ノナン誘導体およびグレリン受容体のアンタゴニストまたは逆アゴニストとしてのそれらの使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8609680B2 (enExample) |
| EP (1) | EP2547679B1 (enExample) |
| JP (1) | JP5496409B2 (enExample) |
| KR (1) | KR101455917B1 (enExample) |
| CN (1) | CN102939290B (enExample) |
| AR (1) | AR080688A1 (enExample) |
| AU (1) | AU2011228699B2 (enExample) |
| BR (1) | BR112012023664B1 (enExample) |
| CA (1) | CA2792234C (enExample) |
| CY (1) | CY1118721T1 (enExample) |
| DK (1) | DK2547679T3 (enExample) |
| ES (1) | ES2557895T3 (enExample) |
| HR (1) | HRP20151232T1 (enExample) |
| HU (1) | HUE025774T2 (enExample) |
| IL (1) | IL221952A (enExample) |
| ME (1) | ME02330B (enExample) |
| MX (1) | MX2012010772A (enExample) |
| PH (1) | PH12012501800A1 (enExample) |
| PL (1) | PL2547679T3 (enExample) |
| PT (1) | PT2547679E (enExample) |
| RS (1) | RS54383B1 (enExample) |
| RU (1) | RU2524341C2 (enExample) |
| SG (1) | SG183812A1 (enExample) |
| SI (1) | SI2547679T1 (enExample) |
| TW (1) | TWI410423B (enExample) |
| WO (1) | WO2011114271A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6165852B2 (ja) | 2012-06-04 | 2017-07-19 | ファイザー・インク | 睡眠障害を治療するためのグレリン受容体逆アゴニストまたはアンタゴニストの使用 |
| SI2861566T1 (sl) * | 2012-06-13 | 2017-03-31 | F. Hoffmann-La Roche Ag | Novi diazaspirocikloalkan in azaspirocikloalkan |
| PL2900669T3 (pl) | 2012-09-25 | 2020-01-31 | F. Hoffmann-La Roche Ag | Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| AU2014356583B2 (en) | 2013-11-26 | 2019-02-28 | F. Hoffmann-La Roche Ag | New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl |
| DK3119782T3 (en) | 2014-03-17 | 2018-03-12 | Remynd Nv Bio Incubator | 2,7-diazaspiro [3.5] NONANFORBINDELSER |
| MA50635A (fr) | 2014-03-26 | 2020-08-12 | Hoffmann La Roche | Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique |
| CR20160418A (es) | 2014-03-26 | 2016-11-07 | Hoffmann La Roche | Nuevos compuestos biciclicos de 7 eslabones |
| CN104610143A (zh) * | 2015-02-12 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途 |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| EP3344619B1 (en) | 2015-09-04 | 2020-10-28 | H. Hoffnabb-La Roche Ag | Phenoxymethyl derivatives |
| AU2016328437A1 (en) | 2015-09-24 | 2018-01-25 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| WO2017050747A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
| MA42918A (fr) | 2015-09-24 | 2018-08-01 | Hoffmann La Roche | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx |
| BR112018006080A2 (pt) | 2015-09-24 | 2018-10-09 | F. Hoffmann-La Roche Ag | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| KR102882225B1 (ko) | 2017-02-21 | 2025-11-07 | 엘지전자 주식회사 | 냉장고 |
| EP3596060B1 (en) | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| US10919852B2 (en) | 2017-07-28 | 2021-02-16 | Chemocentryx, Inc. | Immunomodulator compounds |
| CN108588215A (zh) * | 2018-05-03 | 2018-09-28 | 成都中创清科医学检验所有限公司 | 一种用于检测家族性高胆固醇血症易感性相关的snp位点的引物及其检测方法 |
| CN109970631A (zh) * | 2019-03-26 | 2019-07-05 | 上海吉奉生物科技有限公司 | 一种5-碘-2-吡啶乙酸的合成方法 |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| CN111777559B (zh) * | 2019-04-23 | 2021-11-09 | 苏州大学 | 基于端炔制备多取代吡唑的方法 |
| CN110172062B (zh) * | 2019-06-21 | 2022-01-07 | 南京药石科技股份有限公司 | 一种单氟代螺环化合物的合成方法及其中间体 |
| US11873300B2 (en) * | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
| US12612416B2 (en) | 2020-10-07 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022111624A1 (zh) | 2020-11-27 | 2022-06-02 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| MX2023006770A (es) | 2020-12-10 | 2023-08-14 | Vertex Pharma | Metodos de tratamiento para fibrosis quistica. |
| KR20220001745U (ko) | 2021-01-06 | 2022-07-13 | 성보라 | 자동차시트 후면 보호용 보조커버 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| CA2439152C (en) | 2001-02-28 | 2008-06-17 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| EP1429756B1 (en) | 2001-09-21 | 2006-11-22 | Schering Corporation | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
| WO2003072197A1 (en) | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Acc inhibitors |
| SE0302811D0 (sv) * | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
| EA011086B9 (ru) | 2004-05-12 | 2012-08-30 | Пфайзер Продактс Инк. | Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv |
| GEP20094723B (en) | 2004-05-25 | 2009-07-10 | Pfizer Prod Inc | Tetraazabenzo [e] azulene derivatives and analogs thereof |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| GB0514018D0 (en) | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
| PT1961744E (pt) | 2005-11-18 | 2013-05-15 | Ono Pharmaceutical Co | Composto que contém um grupo básico e sua utilização |
| CA2634940A1 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist |
| EP2010520B1 (en) | 2006-04-20 | 2012-09-12 | Pfizer Products Inc. | Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases |
| JP2010503675A (ja) * | 2006-09-15 | 2010-02-04 | シェーリング コーポレイション | 疼痛、糖尿病および脂質代謝の障害の治療に有用なスピロ縮合アゼチジン誘導体 |
| MX2009002918A (es) * | 2006-09-15 | 2009-03-31 | Schering Corp | Derivados azetidinona y sus metodos de uso. |
| WO2008065508A1 (en) | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Spiroketone acetyl-coa carboxylase inhibitors |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| EP2297164A1 (en) | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| AU2009261248A1 (en) * | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
| CA2729581A1 (en) | 2008-07-29 | 2010-02-04 | Pfizer Inc. | Fluorinated heteroaryls |
| ES2380408T3 (es) | 2008-08-28 | 2012-05-11 | Pfizer Inc. | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
| TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| EP2406230A1 (en) | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| WO2010103437A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
| CA2754523A1 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| TW201038572A (en) * | 2009-03-25 | 2010-11-01 | Gruenenthal Gmbh | Substituted spiro-amide compounds |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| EP2427448A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
| US20120083476A1 (en) * | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| GEP20135907B (en) | 2009-06-05 | 2013-08-12 | Pfizer | L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
-
2011
- 2011-03-11 ES ES11713083.1T patent/ES2557895T3/es active Active
- 2011-03-11 CA CA2792234A patent/CA2792234C/en not_active Expired - Fee Related
- 2011-03-11 BR BR112012023664A patent/BR112012023664B1/pt not_active IP Right Cessation
- 2011-03-11 SI SI201130664T patent/SI2547679T1/sl unknown
- 2011-03-11 JP JP2013500620A patent/JP5496409B2/ja not_active Expired - Fee Related
- 2011-03-11 HR HRP20151232TT patent/HRP20151232T1/hr unknown
- 2011-03-11 PH PH1/2012/501800A patent/PH12012501800A1/en unknown
- 2011-03-11 HU HUE11713083A patent/HUE025774T2/en unknown
- 2011-03-11 DK DK11713083.1T patent/DK2547679T3/en active
- 2011-03-11 SG SG2012062667A patent/SG183812A1/en unknown
- 2011-03-11 MX MX2012010772A patent/MX2012010772A/es active IP Right Grant
- 2011-03-11 RU RU2012137489/04A patent/RU2524341C2/ru not_active IP Right Cessation
- 2011-03-11 CN CN201180014627.7A patent/CN102939290B/zh not_active Expired - Fee Related
- 2011-03-11 PT PT117130831T patent/PT2547679E/pt unknown
- 2011-03-11 ME MEP-2015-189A patent/ME02330B/me unknown
- 2011-03-11 AU AU2011228699A patent/AU2011228699B2/en not_active Ceased
- 2011-03-11 WO PCT/IB2011/051035 patent/WO2011114271A1/en not_active Ceased
- 2011-03-11 KR KR1020127027230A patent/KR101455917B1/ko not_active Expired - Fee Related
- 2011-03-11 RS RS20150808A patent/RS54383B1/sr unknown
- 2011-03-11 EP EP11713083.1A patent/EP2547679B1/en active Active
- 2011-03-11 PL PL11713083T patent/PL2547679T3/pl unknown
- 2011-03-16 US US13/049,225 patent/US8609680B2/en active Active
- 2011-03-16 TW TW100109022A patent/TWI410423B/zh not_active IP Right Cessation
- 2011-03-18 AR ARP110100888A patent/AR080688A1/es not_active Application Discontinuation
-
2012
- 2012-09-13 IL IL221952A patent/IL221952A/en not_active IP Right Cessation
-
2013
- 2013-11-18 US US14/083,275 patent/US20140080756A1/en not_active Abandoned
-
2015
- 2015-12-04 CY CY20151101105T patent/CY1118721T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02330B (me) | Derivati 2,3-dihidro-1h-inden-1-il-2,7-diazaspir0[3.6]nonana i njihova upotreba kao antagonista ili inverznih agonista grelinskog receptora | |
| RU2016140338A (ru) | Азаспиро производные в качестве антагонистов trpm8 | |
| JP2021528467A5 (enExample) | ||
| JP2021519318A5 (enExample) | ||
| JP2014510037A5 (enExample) | ||
| JP2016537384A5 (enExample) | ||
| JP2015504061A5 (enExample) | ||
| US12414952B2 (en) | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | |
| NZ594405A (en) | New adenosine receptor ligands and uses thereof | |
| JP2021528466A5 (enExample) | ||
| HRP20191307T1 (hr) | Spojevi heteroaril-piridona i aza-piridona kao inhibitori aktivnosti btk | |
| JP2016520116A5 (enExample) | ||
| JP2018529731A5 (enExample) | ||
| JP2013519707A5 (enExample) | ||
| JP2022500402A5 (enExample) | ||
| RU2017121278A (ru) | Триазоло-пиразинильные производные, применимые в качестве растворимых активаторов гуанилатциклазы | |
| JP2017535561A5 (enExample) | ||
| JP2015511245A5 (enExample) | ||
| HRP20150868T1 (hr) | Derivati kinolina i kinoksalina kao inhibitori kinaze | |
| RU2017138100A (ru) | Имидазолонилхинолины и их применение в качестве ингибиторов киназы атм | |
| JP2013537210A5 (enExample) | ||
| RU2018112230A (ru) | Бициклические соединения в качестве ингибиторов atx | |
| JP2020502230A5 (enExample) | ||
| JP2016522232A5 (enExample) | ||
| RU2012130436A (ru) | Новое антитромботическое средство |